Table 3.
Expansion of effector T cells in patients with cervical cancer
| % frequency in PBL | % within CD8+ CD45RA+ T cells | |||
|---|---|---|---|---|
| Patients | CD8+ CD45RO+ | CD8+ CD45RA+ | CD28+/CD27+ | CD28−/CD27− |
| Cervical cancer | ||||
| ″CC-I | 6·5 | 16·6 | 60 | 40 |
| ″CC-II | 4 | 7·6 | 87 | 13 |
| ″CC-III | 8 | 17·2 | 88 | 12 |
| ″CC-IV | 3 | 19 | 69 | 31 |
| ″CC-V | 2 | 13·3 | 79 | 21 |
| ″CC-VI | 7 | 11 | 62 | 38 |
| Tuberculosis | ||||
| ″Pat.TUB-I | 4 | 16 | 55 | 45 |
| ″Pat.TUB-II | 5 | 21 | 92 | 8 |
| ″Pat.TUB-III | 10 | 22 | 8 | 92 |
PBL were obtained from patients listed in Table 1 and tested for coexpression of CD8+ CD45RO+ or CD8+ CD45RA+ T cells. The numbers indicate the absolute percentage of these T cell subsets in peripheral blood lymphocytes (PBL). In a parallel experiment, PBL were tested by four-colour flow cytometry (flow cytometer and all directly labelled monoclonal antibodies from Beckman/Coulter, Krefeld, Germany) for expression of CD8, CD45RA, CD27 and CD28. The percentage of CD28+ T cells within the CD8+ CD45RA+ T cell subset is given in the last two rows to the right. Note that CD27 was coregulated with CD28 expression. After flow-cytometry, CD8+ CD45RA+ PBL were sorted based on CD28 expression (see Fig. 1). The percentage of CD8+ T cell subsets from patients TUB-IV and TUB-V in longitudinal studies are depicted in Fig. 3.